Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04850456

Treatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm

Treatment Strategy of Human Gamma Globulin in Children With Severe Infection Complicated With Inflammatory Storm : A Cohort Study

Status
Recruiting
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Children's Hospital of Fudan University · Academic / Other
Sex
All
Age
29 Days – 18 Years
Healthy volunteers
Not accepted

Summary

The inflammatory storm in critically ill patients releases cytokines, causing systemic immune damage, which may be an important cause of multiple organ failure and even death. Inflammatory storms exacerbate the deterioration of the disease in those children. Gamma globulin may be an effective option to control inflammatory storms. However, this preliminary result needs to be verified from reliable and representative RCTs. In our study, we conducted a retrospective study on the use of gamma globulin and an unused control group. At present, the indications of IVIG are mainly focused on the neuromuscular system and the blood system. We hope to establish a more appropriate and operable evaluation table for the suitability of gamma globulin for clinical use.

Detailed description

In severe infective patients who survive the initial inflammatory storm, the immune response often evolves toward a state of immunosuppression, which contributes to increased mortality and severe secondary hospital-acquired infections. However, the role of gamma globulin therapy in patients with severe infection including sepsis and septic shock is discussed controversially. We intend to retrospectively analyze the efficacy and application evaluation of gamma globulin in severely infected children hospitalized in the intensive care unit. Clinical and demographic data, as well as treatment outcome will be collected from the electronic health record. It is expected to provide evaluation basis for clinicians to formulate treatment plans and clinical pharmacists for special comments on the clinical use of gamma globulin.

Conditions

Timeline

Start date
2024-10-01
Primary completion
2026-12-31
Completion
2026-12-31
First posted
2021-04-20
Last updated
2026-03-16

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT04850456. Inclusion in this directory is not an endorsement.